Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy

Item Type:Article
Title:Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy
Creators Name:Schlenker, R. and Olguín-Contreras, L.F. and Leisegang, M. and Schnappinger, J. and Disovic, A. and Rühland, S. and Nelson, P.J. and Leonhardt, H. and Harz, H. and Wilde, S. and Schendel, D.J. and Uckert, W. and Willimsky, G. and Noessner, E.
Abstract:Inherent intermediate-to-low affinity T cell receptors (TCR) that develop during the natural course of immune responses may not allow sufficient activation for tumor elimination, making the majority of T cells suboptimal for adoptive T cell therapy (ATT). TCR affinity enhancement has been implemented to provide stronger T cell activity but carries the risk of creating undesired cross-reactivity leading to potential serious adverse effects in clinical application. We demonstrate here that engineering of low-avidity T cells recognizing a naturally processed and presented tumor-associated antigen with a chimeric PD-1:28 receptor increases effector function to levels seen with high-avidity T cells of identical specificity. Upgrading the function of low-avidity T cells without changing the TCR affinity will allow a large arsenal of low-avidity T cells previously thought to be therapeutically inefficient to be considered for ATT. PD-1:28 engineering re-instated Th1 function in tumor-infiltrating lymphocytes (TILs) that had been functionally disabled in the human renal cell carcinoma (RCC) environment without unleashing undesired Th2 cytokines or IL-10. Involved mechanisms may be correlated to restoration of ERK and AKT signaling pathways. In mouse tumor models of ATT, PD-1:28 engineering enabled low-avidity T cells to proliferate stronger and prevented PD-L1 upregulation and Th2 polarization in the tumor milieu. Engineered T cells combined with checkpoint blockade secreted significantly more IFN-{gamma} compared to T cells without PD-1:28, suggesting a beneficial combination with checkpoint blockade therapy or other therapeutic strategies. Altogether, the supportive effects of PD-1:28 engineering on T cell function makes it an attractive tool for ATT.
Keywords:Adoptive T Cell Therapy, Low-Avidity T Cells, Chimeric PD-1:28, Tumor-Infiltrating Lymphocytes, Cell Engineering, Animals, Mice
Source:Cancer Research
ISSN:0008-5472
Publisher:American Association for Cancer Research (U.S.A.)
Volume:77
Number:13
Page Range:3577-3590
Date:1 July 2017
Official Publication:https://doi.org/10.1158/0008-5472.CAN-16-1922
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library